{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:33:45Z","timestamp":1779204825508,"version":"3.51.4"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T00:00:00Z","timestamp":1190937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2007,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effect of disease\u2010modifying antirheumatic drugs (DMARDs) on the likelihood of patients with rheumatoid arthritis (RA) developing septic arthritis (SA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The United Kingdom General Practice Research Database (GPRD) was used to identify adults with RA, and age\u2010, sex\u2010, and practice\u2010matched control subjects. Subjects were studied between 1987 and 2002. The risk of developing SA (excluding infected joint replacements) for individuals with RA was calculated and the effect of DMARD use determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 136,977 subjects (34,250 patients with RA, 102,747 controls) were identified. SA was identified in 345 subjects, of which 321 (236 in patients with RA, 85 in controls) cases occurred during the study period. The incidence rate of SA was 12.9 times higher in subjects with RA than in those without (95% confidence interval [95% CI] 10.1\u201316.5, <jats:italic>P<\/jats:italic> &lt; 0.001). The incident rate ratios (IRRs) for developing SA while receiving DMARDs compared with receiving no DMARDs were different for different medications. Penicillamine (adjusted IRR 2.51, 95% CI 1.29\u20134.89, <jats:italic>P<\/jats:italic> = 0.004), sulfasalazine (adjusted IRR 1.74, 95% CI 1.04\u20132.91, <jats:italic>P<\/jats:italic> = 0.03), and prednisolone (adjusted IRR 2.94, 95% CI 1.93\u20134.46, <jats:italic>P<\/jats:italic> &lt; 0.001) were associated with an increased incidence of SA when compared with not receiving any DMARD. The use of other DMARDs including methotrexate showed no such effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Individuals with RA have an increased risk of developing SA. This increased risk can be attributed to both the disease process and the use of DMARDs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.23003","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T22:24:51Z","timestamp":1191018291000},"page":"1151-1157","source":"Crossref","is-referenced-by-count":79,"title":["The importance of the disease process and disease\u2010modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis"],"prefix":"10.1002","volume":"57","author":[{"given":"Christopher J.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjeerd P.","family":"van Staa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel K.","family":"Arden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei024"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0219-0494.2003.00019.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.6.458"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381215"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.1.24"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040165"},{"key":"e_1_2_8_8_2","volume-title":"The general practice research database: information for researchers","year":"1996"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2630010108"},{"key":"e_1_2_8_10_2","volume-title":"General practice research database (GPRD): scope and quality of data","author":"Hollowell J","year":"1994"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00137-F"},{"key":"e_1_2_8_12_2","first-page":"259","article-title":"Research implications of computerised primary care","volume":"5","author":"Mann RD","year":"1992","journal-title":"Post Marketing Surveillance"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1383"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04248-7"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1557(200009\/10)9:5<359::AID-PDS507>3.0.CO;2-E"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.698"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.3.370"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400516"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.8.470"},{"key":"e_1_2_8_20_2","first-page":"CD001157","article-title":"Cyclophosphamide for treating rheumatoid arthritis","volume":"4","author":"Suarez\u2010Almazor ME","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1998.00311.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225150-00004"},{"key":"e_1_2_8_23_2","first-page":"2461","article-title":"Fatal outcome of Aspergillus fumigatus arthritis in a renal transplant recipient","volume":"2","author":"Cassuto\u2010Viguier E","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200311000-00023"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.6.653"},{"key":"e_1_2_8_26_2","first-page":"2125","article-title":"Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti\u2010tumor necrosis factor\u2010alpha treatment","volume":"32","author":"Bassetti S","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000055092.90609.e5"},{"key":"e_1_2_8_28_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/00365540410021171-1","article-title":"Septic arthritis due to Salmonella enteritidis associated with infliximab use","volume":"37","author":"Katsarolis I","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"e_1_2_8_29_2","first-page":"1663","article-title":"Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti\u2010tumor necrosis factor\u2010alpha therapy","volume":"31","author":"Kaur PP","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000158551.39738.de"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006270"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20876"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.2537-2541.2005"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.23003","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.23003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:23:31Z","timestamp":1700011411000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,28]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10,15]]}},"alternative-id":["10.1002\/art.23003"],"URL":"https:\/\/doi.org\/10.1002\/art.23003","archive":["Portico"],"relation":{},"ISSN":["0893-7524","1529-0123"],"issn-type":[{"value":"0893-7524","type":"print"},{"value":"1529-0123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,28]]}}}